PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 6, 2012, Pages 893-899

  Yun, Seok Joong ^a   Jo, Sung Whan ^a   Ha, Yun Sok ^a   Lee, Ok Jun ^a   Kim, Won Tae ^a   Kim, Yong June ^a   Lee, Sang Cheol ^a   Kim, Wun Jae ^a  

^a Chungbuk National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA;

CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM GRADING; NEOPLASM STAGING; PHOSPHOFRUCTOKINASE-2; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84870569070     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.08.018     Document Type: Article

References (22)

1. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2,596 patients from seven EORTC trials. Eur Urol 2006, 49:465-466. Discussion 467-75.
2. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
3. Ratcliffe P.J., O'Rourke J.F., Maxwell P.H., et al. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 1998, 201:1153-1162.
4. Bruick R.K. Oxygen sensing in the hypoxic response pathway: Regulation of the hypoxia-inducible transcription factor. Genes Dev 2003, 17:2614-2623.
5. Kawaguchi T., Veech R.L., Uyeda K. Regulation of energy metabolism in macrophages during hypoxia. Roles of fructose 2,6-bisphosphate and ribose 1,5-bisphosphate. J Biol Chem 2001, 276:28554-28561.
6. Okar D.A., Lange A.J. Fructose-2,6-bisphosphate and control of carbohydrate metabolism in eukaryotes. Biofactors 1999, 10:1-14.
7. Okar D.A., Manzano A., Navarro-Sabate A., et al. PFK-2/FBPase-2: Maker and breaker of the essential biofactor fructose-2,6-bisphosphate. Trends Biochem Sci 2001, 26:30-35.
8. Minchenko O.H., Ochiai A., Opentanova I.L., et al. Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors. Biochimie 2005, 87:1005-1010.
9. Minchenko O.H., Opentanova I.L., Ogura T., et al. Expression and hypoxia-responsiveness of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 in mammary gland malignant cell lines. Acta Biochim Pol 2005, 52:881-888.
10. Bobarykina A.Y., Minchenko D.O., Opentanova I.L., et al. Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers. Acta Biochim Pol 2006, 53:789-799.
11. Yalcin A., Telang S., Clem B., et al. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol 2009, 86:174-179.
12. Sakata J., Abe Y., Uyeda K. Molecular cloning of the DNA and expression and characterization of rat testes fructose-6-phosphate,2-kinase:fructose-2,6-bisphosphatase. J Biol Chem 1991, 266:15764-15770.
13. Kim W.J., Kim E.J., Kim S.K., et al. Predictive value of progression-related gene classifier in primary non-muscle-invasive bladder cancer. Mol Cancer 2010, 9:3.
14. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008, 54:303-314.
15. Greene F.L. The American Joint Committee on Cancer: Updating the strategies in cancer staging. Bull Am Coll Surg 2002, 87:13-15.
16. Hall M.C., Chang S.S., Dalbagni G., et al. Guideline for the management of non-muscle-invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007, 178:2314-2330.
17. Sinicrope F.A., Ruan S.B., Cleary K.R., et al. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995, 55:237-241.
18. Bland J.M., Altman D.G. Transformations, means, and confidence intervals. BMJ 1996, 312:1079.
19. Hockel M., Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93:266-276.
20. Shariat S.F., Zippe C., Ludecke G., et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1, or CIS transitional cell carcinoma of the bladder. J Urol 2005, 173:1518-1525.
21. Hong S.J., Cho K.S., Han M., et al. Nomograms for prediction of disease recurrence in patients with primary Ta, T1 transitional cell carcinoma of the bladder. J Korean Med Sci 2008, 23:428-433.
22. Habuchi T., Marberger M., Droller M.J., et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 2005, 66:64-74.